Search
Search Results
-
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis
IntroductionAndrogen receptor targeted agents (ARTA) have increasingly been incorporated into treatment regimens for various stages of prostate...
-
Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment
The biological function of the male hormones (androgens) is orchestrated through the activation of the androgen receptor-mediated signaling events...
-
Androgen receptor function and targeted therapeutics across breast cancer subtypes
Despite significant progress in breast cancer (BC) therapy, it is globally the most commonly diagnosed cancer and leads to the death of over 650,000...
-
New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium
The androgen receptor (AR) is a crucial player in various aspects of male reproduction and has been associated with the development and progression...
-
Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment
The biological function of the male hormones (androgens) is orchestrated through the activation of the androgen receptor-mediated signaling events...
-
Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy
Extensive exploration of the molecular subtypes of triple-negative breast cancer (TNBC) is critical for advancing precision medicine. Notably, the...
-
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer
BackgroundResistance to androgen receptor signalling inhibitors (ARSIs) represents a major clinical challenge in prostate cancer. We previously...
-
Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor
BackgroundProstate cancer is dependent on androgen receptor (AR) signaling, and androgen deprivation therapy (ADT) has proven effective in targeting...
-
A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model
Prostate cancer (PCa) is the second most prevalent malignancy among men worldwide. The aberrant activation of androgen receptor (AR) signaling has...
-
MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome
MicroRNAs (miRNAs) are small RNA molecules that regulate genes and are involved in various biological processes, including cancer development....
-
Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features
According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors...
-
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer
PurposeRadiation therapy (RT) and hormone receptor (HR) inhibition are used for the treatment of HR-positive breast cancers; however, little is known...
-
Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
Although androgen receptor (AR) can influence bladder cancer (BCa) initiation and progression, its impact on tumor immune escape remains unclear....
-
Secreted indicators of androgen receptor activity in breast cancer pre-clinical models
PurposeAccumulating evidence has attracted attention to the androgen receptor (AR) as a biomarker and therapeutic target in breast cancer. We...
-
Resistance to Targeted Therapy in Breast Cancer
The discoveries of breast cancer molecular subtypes and their deregulated pathways have given rise to the emergence of potential therapeutic targets...
-
Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest
BackgroundTherapies for metastatic castration-resistant prostate cancer (mCRPC) include targeting the androgen receptor (AR) with androgen receptor...
-
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer
Androgen receptor (AR) is an important prognostic marker and therapeutic target in luminal androgen receptor triple-negative breast cancer (LAR TNBC)...
-
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer
Prostate cancer is the most commonly diagnosed cancer but the management of advanced prostate cancer remains a therapeutic challenge, despite the...
-
Androgen and Oestrogen Signalling Pathways in Prostate Hyperplastic Tissues: Opportunities for Therapeutic Targeting from Multiple Angles
Benign prostatic hyperplasia (BPH), a non-malignant neoplasm in ageing men, is the most frequent cause of urinary flow obstructions at the bladder...
-
Bladder Cancer Prevention: Potential Molecular Targets and Their Clinically Relevant Agents
Purpose of ReviewThis review summarizes the druggable targets within the critical signaling pathways and the promising clinically relevant drugs...
